Form 8-K - Current report:
SEC Accession No. 0001370053-25-000023
Filing Date
2025-02-27
Accepted
2025-02-27 16:17:39
Documents
15
Period of Report
2025-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K anab-20250227.htm   iXBRL 8-K 24186
2 EX-99.1 q42024earningsrelease.htm EX-99.1 109544
  Complete submission text file 0001370053-25-000023.txt   311027

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anab-20250227.xsd EX-101.SCH 2058
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT anab-20250227_def.xml EX-101.DEF 8934
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anab-20250227_lab.xml EX-101.LAB 30000
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anab-20250227_pre.xml EX-101.PRE 20656
17 EXTRACTED XBRL INSTANCE DOCUMENT anab-20250227_htm.xml XML 2817
Mailing Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121
Business Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 858-362-6295
ANAPTYSBIO, INC (Filer) CIK: 0001370053 (see all company filings)

EIN.: 203828755 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37985 | Film No.: 25679078
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)